Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
about
The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemPopulation pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistanceAppraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections.Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelPharmacodynamic variability beyond that explained by MICs.Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.Characteristics of doripenem: a new broad-spectrum antibiotic.Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.Novel treatment approach to combat an infection with Acinetobacter.Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
P2860
Q28289744-496373E4-2B38-42A6-A729-FE68AFD42B8EQ33553063-560487CB-B84B-4F03-BDAD-00D44B9A2EBAQ33876543-263DA6CA-1941-4FFE-A376-940DB9F98F39Q34003193-82C8D688-BDD3-4FFF-AC95-06F7ADF84B34Q34529381-FB09B03C-EC19-4133-8933-76E79683FA73Q35026526-BCC81750-2E3F-44B5-A420-3089CD5377FAQ35076943-FD9E3058-4A6F-4817-B916-248048B5114AQ35666586-D878AF91-2917-47C0-B9AF-28EFA199A712Q36276852-26740AB9-7B20-44E8-9C32-03CC4999ACA3Q36757639-D45DCE01-9623-46FB-A304-9507213EF3CDQ36785877-0CFA98EA-E837-4A60-A067-3B288D0C6BD4Q36902744-9E435894-83D8-4B9B-8BB1-5F53A737B8E7Q37263324-14FAFA4E-7C4E-4BB1-A8A0-1B0A091A0BDDQ38058355-F6B95A7B-4292-4307-8290-FAD0D2627128Q38073197-4D03012E-8BF8-4293-B636-DB38847E582FQ38751264-A1960943-B067-4E3E-8C8A-1768F986ABB3Q40749626-F7E51F6F-BC5A-475D-907E-03825A451323Q41656519-5AB248F4-7C3C-4D64-9650-BC8D6DB1C736Q42049594-0620B772-0E72-45E8-BFAF-ADFE90FB7C13Q42706267-C7F039D8-B799-4F25-8942-E9D69BDA5A89Q42940038-AD440CF6-BAD3-4180-9EF0-20A0DCC5E95CQ43119954-8EDF333E-4C3A-421A-8E8E-46EB8B8F63C2
P2860
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@en
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@nl
type
label
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@en
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@nl
prefLabel
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@en
Pharmacokinetic-pharmacodynami ...... n for critically ill patients.
@nl
P2093
P1476
Pharmacokinetic-pharmacodynami ...... on for critically ill patients
@en
P2093
Paul G Ambrose
Scott A Van Wart
Sujata M Bhavnani
P304
P356
10.1016/J.DIAGMICROBIO.2009.01.027
P50
P577
2009-02-26T00:00:00Z